A group led by scientists at The University of Texas at Austin has discovered a brand-new, bio-inspired medication that restores the capability of immune cells to combat cancer. The medication increases the effectiveness of immunotherapy and inhibits tumour growth in mice models of melanoma,
Cancer-related fatigue (CRF) affects patients' quality of life while they are undergoing treatment and is a debilitating yet all-too-common condition. For the constellation of symptoms that make up CRF, there are currently no effective pharmaceutical treatments.
A recent study from Australian and Dutch experts revealed that older patients with kidney tumours who are not candidates for surgery may benefit from targeted, high-dose radiation.
Macrophages are white blood cells that serve as the body's first line of defence against infection. Macrophages can launch a reaction against tumours in addition to destroying dangerous germs. However, macrophages, like other cells, can reach a state known as senescence, which is associated
In individuals with specific malignancies, including as head and neck squamous cell carcinoma and lung adenocarcinoma, a combination of inhibitors has been shown to reduce tumour growth and prevent relapse. Their findings encourage the creation of novel therapy modalities that specifically t
The new device, the size and shape of a grain of rice, can run dozens of trials at once to evaluate the impact of novel medicines on some of the most difficult-to-treat brain malignancies.
A recent study from the University of Michigan Department of Neurosurgery and Rogel Cancer Centre demonstrates encouraging preliminary findings that a therapy combining cell-killing and immune-stimulating drugs is safe and effective in extending survival for patients with gliomas, a particu
The therapy, tested in mouse models, combines a delivery system that targets cancer cells with a specially modified version of microRNA-34a, a molecule that acts “like the brakes on a car,” slowing or stopping cell division, said Andrea Kasinski, lead author and the William and Patty Miller
Treatment for over 80 per cent of breast cancer survivors does not end with surgery, radiation, and chemotherapy. Instead, doctors advise them to take medication to inhibit sex hormones, which can fuel tumour growth and cause recurrence, for the next five to ten years.
A study performed by UCLA Jonsson Comprehensive Cancer Centre researchers gave new light on why tumours that have spread to the brain from other parts of the body react to immunotherapy whereas glioblastoma, an aggressive brain cancer, does not.